Despite Amarin, ITC May Be Right Prescription For Pharma
Law360 (June 4, 2019, 10:48 AM EDT) -- Foreign-made drugs, nutritional supplements and medical devices imported into the United States with false or misleading labeling or designed to look like an established competing product in violation of the Lanham Act could also violate 19 U.S.C. § 1337, and thus may be stopped at the U.S. border by U.S. Customs and Border Protection based on an exclusion order issued by the U.S. International Trade Commission.
False advertising claims in the life sciences sector frequently involve false or misleading statements about a product’s composition, its efficacy for treating a disease, its regulatory approval status, and similarities and differences with respect to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!